


13. (original) The method according to claim 1, wherein the histone deacetylase inhibitor is a compound of the formula

(Xe)



or a pharmaceutically acceptable salt thereof.

14. (currently amended) The method according to ~~any one of~~ claim 1, wherein the histone deacetylase inhibitor is selected from the group consisting of N-hydroxy-3-[4-[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, N-hydroxy-3-[4-[[[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide and N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide, or, in each case a pharmaceutically acceptable salt thereof.


Claims 15-20 (cancelled).

21. (withdrawn) A pharmaceutical composition comprising (a) a FLT-3 inhibitor and (b) a histone deacetylase inhibitor for the treatment of myelodysplastic syndromes, lymphomas and leukemias and solid tumors.

22. (withdrawn) A pharmaceutical composition according to claim 21 for treating acute myeloid leukemia (AML), colorectal cancer (CRC) or non-small cell lung cancer (NSCLC).

23. (withdrawn) A pharmaceutical composition according to claim 21, wherein the FLT-3 inhibitor is -[(9*S*,10*R*,11*R*,13*R*)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1*H*,9*H*-diindolo[1,2,3-*gh*:3',2',1'-*lm*]pyrrolo[3,4-*j*][1,7]benzodiazonin-11-yl]-*N*-methylbenzamide of the formula (VII):

24. (new) The method according to claim 2, wherein the staurosporine derivative is *N*-[(9*S*,10*R*,11*R*,13*R*)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1*H*,9*H*-diindolo[1,2,3-*gh*:3',2',1'-*lm*]pyrrolo[3,4-*j*][1,7]benzodiazonin-11-yl]-*N*-methylbenzamide of the formula (VII):



(VII)

or a salt thereof and the HDAI is selected from the group consisting of *N*-hydroxy-3-[4-[[[2-hydroxyethyl][2-(1*H*-indol-3-yl)ethyl]-amino]methyl]phenyl]-2*E*-2-propenamide, *N*-hydroxy-3-[4-[[[2-(1*H*-indol-3-yl)ethyl]-amino]methyl]phenyl]-2*E*-2-propenamide and *N*-hydroxy-3-[4-[[[2-(2-methyl-1*H*-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2*E*-2-propenamide, or, in each case a pharmaceutically acceptable salt thereof.